Gene Linked to Vitamin D Metabolism Emerges as New Target in Cancer Treatment

A study published in Frontiers in Endocrinology has identified the gene SDR42E1 as a key regulator of vitamin D metabolism and a promising target in cancer therapy. Researchers found that disabling SDR42E1, which is essential for converting vitamin D into its active form, significantly reduced cancer cell growth. Using CRISPR/Cas9 gene editing, scientists deactivated SDR42E1 in colorectal cancer cells, resulting in a 53% drop in cell viability and altered expression in over 4,600 genes involved in cancer signaling and lipid metabolism.

Lead author and senior author suggest that blocking SDR42E1 may selectively kill cancer cells without harming healthy ones. Beyond oncology, the team notes that enhancing SDR42E1 expression might benefit conditions influenced by vitamin D, such as kidney disease and autoimmune disorders. However, they caution that further research is needed to understand its broader, long-term effects on vitamin D balance.

22-07-2025